This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating the recent FDA approval of Gamifant (emapalumab-lzsg), the first treatment for Macrophage Activation Syndrome in Still's disease

Ticker(s): SOBI.XSTO

Who's the expert?

Institution: University of Pittsburgh Medical Center

  • Assistant Professor of Medicine and Staff Rheumatologist-University of Pittsburgh Medical Center.
  • Manages 80 patients/yr with Myositis; 50 patients/yr with Sjogren's Disease,180 patients with rheumatoid arthritis, and 50 patients with Systemic Lupus Erythematosus.
  • Research interests include inflammatory myopathies and biomarker clinical studies.

Interview Goal
This call will feature a discussion on the current standard of care for MAS and the potential of Gamifant from Sobi.

Are You Interested In These Questions?

Slingshot Insights Explained
6Hours Left to Join Project
Call Date
Sep 18, 2025
Call Time
05:00 PM EDT
Wall Street Time

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.